Melody Cobleigh to Neoplasm Metastasis
This is a "connection" page, showing publications Melody Cobleigh has written about Neoplasm Metastasis.
Connection Strength
1.018
-
Targeting metastatic and advanced breast cancer. Semin Oncol Nurs. 2007 Feb; 23(1):37-45.
Score: 0.281
-
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113.
Score: 0.171
-
Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. Breast Cancer Res Treat. 2019 Sep; 177(2):325-333.
Score: 0.166
-
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003 Oct; 30(5 Suppl 16):117-24.
Score: 0.056
-
Is trastuzumab every three weeks ready for prime time? J Clin Oncol. 2003 Nov 01; 21(21):3900-1.
Score: 0.056
-
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222.
Score: 0.042
-
Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors. Cancer Treat Res. 1998; 94:209-30.
Score: 0.037
-
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5687-5695.
Score: 0.036
-
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9.
Score: 0.027
-
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81.
Score: 0.023
-
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May; 115(1):115-21.
Score: 0.019
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.
Score: 0.019
-
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2786-92.
Score: 0.017
-
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6.
Score: 0.016
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):792-9.
Score: 0.015
-
Phase II study of vindesine in patients with metastatic breast cancer. Cancer Treat Rep. 1981 Jul-Aug; 65(7-8):659-63.
Score: 0.012
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.012
-
Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant. 1995 Nov; 1(1):40-6.
Score: 0.008
-
Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol. 1994 Feb; 12(2):342-6.
Score: 0.007